Boehringer Ingelheim Kg

Boehringer Ingelheim Gmbh

C. H. Boehringer Sohn

Boehringer Ingelheim Zentrale

Franz J Kuhn

Karl-Heinz Weber

Erich Lehr

Gerhard Walther

Helmut Ensinger

Claus S Schneider

Dieter Hinzen

Werner Stransky

Adolf Langbein

Peter Danneberg

Gunter Schingnitz

Ulrike Kufner-Muhl

Enzio Muller

Otto Roos

Walter Losel

Adolf Bauer

Wolfgang Troger

Karl H Weber

Dietrich Arndts

Karin Boke

Ilse Strelle

Herbert Koppe

Werner Kummer

Helmut Stahle

Richard Reichl

Matthias Grauert

Franz Esser

Wolfgang Hoefke

Herbert Merz

Klaus Stockhaus

Werner Traunecker

Joachim Mierau

Adrian Carter

Ilse Streller

Enzio Mueller

Gerhard Waither

Gerhard Walther, Deceased

The invention relates to the use of carbocyclically and heterocycally fused dihydroyridines as cerebroprotective agents, as agents for treating chronic inflammatory processes and as agents for inhabiting blood clotting, and also relates to new compounds of formula Ie ##STR1##

Pharmaceutically useful 3,4-dihydroisoquinoline

Novel benzomorphan derivatives of the formula ##STR1## wherein R.sup.1 -R.sup.8 are as defined herein. The benzomorphan derivatives are useful for treating cerebral ischaemia of various origins, epilepsy and neurodegenerative diseases.

Benzomorphan derivatives

Xanthine derivatives of formula ##STR1## wherein R.sub.1 is hydrogen, alkyl or alkynyl, R.sub.2 is different and is alkyl, alkynyl, phenyl-alkylene, phenyl alkenylene, cycloalkyl, inter alia, R.sub.3 is cycloalkyl, phenyl, norbornane, inter alia and R.sub.4 is hydrogen, methyl, benzyl, inter alia.

Asymmetrically substituted xanthines

The invention relates to new xanthine derivatives of general formula I, processes for preparing them and their use as pharmaceutical compositions.

Xanthine derivatives with adenosine-antagonistic activity

Bornyl xanthine derivatives with adenosine-antagonistic activity

The invention relates to the use of carbocyclically and heterocyclically fused dihydropyridines as cerebroprotective agents, as agents for treating chronic inflammatory processes and as agents for inhibiting blood clotting, and also relates to new compounds of formula Ie ##STR1##

Anti-inflammatory method

Cerebroprojection method

New xanthine compounds of formula I: ##STR1## wherein the substituents are defined herein, which xanthines are useful as adenosine antagonists.

8-substituted 1,3-dialiphaticxanthine derivatives

Xanthines of the formula I ##STR1## wherein R.sub.1 is a C.sub.1 -C.sub.4 alkyl group:

The invention relates to new quinuclidines, processes for their preparation and their use as medicaments having cholinomimetic properties.

Quinuclidines, their use as medicaments and processes for their

The invention relates to quinuclidines, processes for their preparation and their use as medicaments having cholinomimetic properties.

The invention relates to new tetrahydropyridine derivatives, processes for preparing them and their use as pharmaceutical compositions with cholinomimetic properties.

Tetrahydropyridine derivatives

Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or alkyl of 1 to 4 carbon atoms; R.sub.2 is 2-, 3- or 4-pyridyl, phenyl or mono- or di-substituted phenyl, where the substituents are each individually alkoxy of 1 to 2 carbon atoms, fluorine, chlorine, bromine, trifluoromethyl, alkyl or 1 to 4 carbon atoms, hydroxyl or nitro; and

N-heterocyclic substituted -pyrrolidin-2-ones

1-(benzyl or pyridylmethyl)-4 or 5-aminomethyl-pyrrolidin-2-ones

Growing community of inventors

Gau-Algesheim, Germany

Franz J Kuhn